Sana Biotechnology, Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. This is an annual report; the supplied filing text does not provide clear standalone fourth-quarter results.
Business context
Sana is a preclinical-stage biotechnology company developing ex vivo cell therapies and in vivo cell-engineering technologies for oncology, diabetes, CNS, cardiovascular, and genetic diseases. Its platforms center on hypoimmune cells designed to evade immune rejection and fusosomes intended to deliver therapeutic payloads to selected cells. All product candidates were preclinical, and none had entered clinical development or been approved for sale at year-end.
Financial performance and position
| Metric | FY2021 | FY2020 |
|---|---|---|
| Product revenue | None | None |
| Research and development expense | $248.6 million | $132.9 million |
| Success payment and contingent consideration expense | $57.9 million | $124.9 million |
| General and administrative expense | $50.4 million | $28.3 million |
| Total operating expenses / operating loss | $356.9 million | $286.1 million |
| Net loss | $355.9 million | $285.3 million |
| Net loss per share, basic and diluted | $2.14 | $21.92 |
| Cash used in operating activities | $251.1 million | $138.0 million |
Margins: Gross margin is not applicable because Sana had no product revenue. Losses reflect operating expenses rather than commercial sales activity.
Liquidity and balance sheet: Cash, cash equivalents, and marketable securities totaled $746.9 million at December 31, 2021, compared with $412.0 million at year-end 2020. Total assets were $1.129 billion and total liabilities were $400.9 million. The company had no debt outstanding. Management stated that year-end liquidity was expected to fund operating and capital needs for at least 12 months, while noting that estimates depend on assumptions and additional financing is expected to be needed over time.
Cash flows and financing: Investing activities used $245.8 million, including net marketable-security purchases and $29.9 million of property and equipment purchases. Financing activities provided $631.8 million, primarily from $626.4 million of net IPO proceeds. The IPO closed in February 2021 at $25 per share.
Material changes versus FY2020
- Net loss increased by $70.6 million, or about 25%; operating cash use increased by $113.1 million.
- R&D expense rose $115.7 million, driven by a $50.0 million Beam gene-editing license payment, higher staffing, research and laboratory costs, and facility costs.
- G&A expense increased $22.1 million, including higher personnel, legal, public-company insurance, and consulting costs.
- Fair-value expense for success payments and contingent consideration fell by $67.1 million, partially offsetting higher underlying R&D and G&A spending. These non-cash revaluations can make reported losses volatile.
- The IPO materially expanded liquidity and converted preferred stock into common stock. Common shares outstanding were 184.9 million at year-end 2021, versus 16.2 million at year-end 2020; the figures reflect the IPO conversion and issuance as well as other share activity.
Outlook, commentary, risks, and unusual items
- Management targeted 2022 IND submissions for SC291, an allogeneic CD19 CAR T candidate, and SG295, an in vivo CD19 CAR T candidate. It described SC451 beta-cell therapy as potentially reaching IND submission as early as 2023; these are goals, not assured outcomes.
- Management reported modest COVID-19-related delays in discovery and development, primarily from temporary partial shutdowns at certain CROs and academic institutions; those operations had resumed. Further effects on studies, suppliers, manufacturing buildout, and future trials remained uncertain.
- The company entered a long-term lease for a planned Fremont GMP manufacturing facility in 2021. Management said buildout and readiness would take several years; execution, cost, staffing, regulatory compliance, and technology transfer are material risks.
- Reported results include significant non-cash remeasurement of Cobalt contingent consideration and Cobalt and Harvard success-payment liabilities. At year-end, these liabilities totaled approximately $256.3 million, including $153.7 million of contingent consideration and $102.5 million of success-payment liabilities. Potential contractual payments are larger: up to $500 million of Cobalt contingent consideration, up to $500 million of Cobalt success payments, and up to $175 million of Harvard success payments, subject to triggering conditions.
- Operating lease commitments totaled $181.1 million in undiscounted payments at year-end. The filing reports no material legal proceedings. The auditor issued an unqualified opinion on the financial statements; management concluded disclosure controls and internal control over financial reporting were effective, but the auditor did not attest to internal-control effectiveness because of the company’s emerging-growth-company exemption.
- Key risks include unproven platforms and preclinical-only evidence, clinical and regulatory uncertainty, complex manufacturing and supply dependencies, competition, intellectual-property and licensing risks, future financing needs, and potential dilution or cash demands from contingent obligations.
Important facts for investors to verify
- Whether SC291 and SG295 achieve the stated IND timelines, and whether regulators permit trials to proceed.
- How rapidly the $746.9 million of year-end liquidity is consumed, including clinical and manufacturing investment, and whether the stated minimum 12-month runway remains applicable.
- The assumptions and sensitivity behind fair-value liabilities and potential milestone, royalty, and success-payment obligations.
- Fremont facility buildout costs, schedule, operational readiness, and dependence on CDMOs and specialized supplies.
- Whether preclinical findings translate to human safety and efficacy, particularly for immune evasion, gene editing, and stem-cell-derived products.